GNPX

$2.02

Pre-MarketAs of Mar 17, 8:00 PM UTC

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Recent News

Associated Press Finance
Sep 8, 2025

BC-Most Active Stocks

td class="col-issue">Next Technology Holding Inc.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.